Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease

European Heart Journal

Volumn 30, Issue 15, 2009, Pages 1837-1843

  Recio Mayoral, Alejandro ^a   Mason, Justin C ^a   Kaski, Juan C ^b   Rubens, Michael B ^c   Harari, Olivier A ^a   Camici, Paolo G ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Coronary circulation; Inflammation; Myocardial blood flow; Positron emission tomography; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DISEASE ACTIVITY; DISEASE DURATION; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; HYPEREMIA; MALE; MICROANGIOPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADENOSINE; ADULT; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICROCIRCULATION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RISK ASSESSMENT; VASODILATOR AGENTS;

EID: 68749087307     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp205     Document Type: Article

References (46)

1. Abou-Raya S, Abou-Raya A, Nairn A, Abuelkheir H. Chronic inflammatory autoimmune disorders and atherosclerosis. Ann NY Acad Sci 2007: 1107:56-67.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997: 145:408-415.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001: 44:2331-2337.
4. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001: 44:2737-2745.
5. Sattar N, McCarey DW, Capell H, Mclnnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003: 108:2957-2963.
6. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004: 109:112-1110.
7. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999: 340: 115-126.
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Grculation 2002; 105:1135-1143.
9. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007: 356: 830-840.
10. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000: 102:1233-1238.
11. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 2005: 46:75-88.
12. Ciftci O, Yilmaz S, Topcu S, Caliskan M, Gullu H, Erdogan D, Pamuk BO, Yildirir A, Muderrisoglu H. Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 2008; 198:332-337.
13. Hirata K, Kadirvelu A, Kinjo M, Sciacca R, Sugioka K, Otsuka R, Choy A, Chow SK, Yoshiyama M, Yoshikawa J, Homma S, Lang CC. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum 2007: 56:1904-1909.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982: 25:1271-1277.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988: 31:315-324.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creati-nine. Nephron 1976: 16:31-41.
17. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007: 66:407-409.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992: 35:630-640.
19. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979: 300:1350-1358.
20. Naoumova RP, Kindler H, Leccisotti L, Mongillo M, Khan MT, Neuwirth C, Seed M, Holvoet P, Betteridge J, Camici PG. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperli-pidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cordiol 2007; 50:2051-2058.
21. Camici P, Marraccini P, Marzilli M, Lorenzoni R, Buzzigoli G, Puntoni R, Boni C, Bellina CR, Klassen GA, L'Abbate A, Ferrannini E. Coronary hemodynamics and myocardial metabolism during and after pacing stress in normal humans. Am J Physiol 1989; 257:E309-E317.
22. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994; 330:1782-1788.
23. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythema-tosus. N Engl J Med 2003; 349:2407-2415.
24. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-2406.
25. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51:447-450.
26. El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, Bernstein RM, Bruce IN. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110:399-404.
27. Wright SA, O'Prey FM, Rea DJ, Plumb RD, Gamble AJ, Leahey WJ, Devine AB, McGivern RC, Johnston DG, Finch MB, Bell AL, McVeigh GE. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arteriosder Thromb Vasc Biol 2006; 26:2281-2287.
28. Bottcher M, Madsen MM, Refsgaard J, Buus NH, Dorup I, Nielsen TT, Sorensen K Peripheral flow response to transient arterial forearm occlusion does not reflect myocardial perfusion reserve. Circulation 2001; 103:1109-1114.
29. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, Romas E, Clemens L, Dragicevic G, Harianto H, Wicks I, McColl G, Best J, Jenkins A. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48:81-89.
30. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001; 37: 1075-1082.
31. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, Ishimura E, Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:1489-1497.
32. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82:407-413.
33. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, Manzi S. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50:151-159.
34. Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, Shook B, Tracy RP, Kuller LH, Brockwell S, Manzi S. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008; 58:835-842.
35. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44:1473-1482.
36. Raza K, Thambyrajah J, Townend JN, Exley AR, Hortas C, Filer A, Carruthers DM, Bacon PA. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000; 102:1470-1472.
37. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106:2184-2187.
38. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologies Register. Arthritis Rheum 2007; 56: 2905-2912.
39. Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE, Frey D, Hermann M, Riesen W, Neidhart M, Michel BA, Hellermann JP, Gay RE, Luscher TF, Gay S, Noll G, Ruschitzka F. Simvastatin improves endothelial function in patients with rheumatoid arthritis, J Am Coll Cardiol 2005; 45:461-464.
40. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Kunzler P, Enseleit F, Periat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008; 117:2262-2269.
41. Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, Wilkinson IB. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50:852-858.
42. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
43. Romero F, Rodriguez-lturbe B, Pons H, Parra G, Quiroz Y, Rincon J, Gonzalez L Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 2000; 152:127-133.
44. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegard J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104:1887-1893.
45. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by auto reactivity. J Clin Invest 1996; 97: 2027-2037.
46. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E. CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004; 109:2744-2748.